INTERPHEX Opens Registration for 2026 with Expanded Show Floor, Education and Debut of New Contract and Outsourcing Exchange

RX has opened registration for INTERPHEX 2026, running 21 to 23 April at the Javits Center in New York. The show covers pharmaceutical and biotechnology development and manufacturing across the full value chain, including medtech, regulatory compliance and supply chain efficiency, and expects around 9,000 professionals, more than 600 suppliers and over 140 speakers. The main addition this year is the Contract and Outsourcing Exchange, a show-within-a-show bringing together contract development and manufacturing organisations, pharma and biotech leaders and emerging companies. It includes a dedicated area for early-stage biotech firms and investor-informed panels on manufacturing readiness and scalability. Education runs as two tracks across three stages inside an enclosed Learning Lab, with content vetted by a Scientific Programming Advisory Committee formed in partnership with AAPS. The first track covers manufacturing innovation and process excellence, the second global regulatory excellence and supply sustainability, with topics including secure supply chains, facility design, AI-driven innovation and EU Annex 1 requirements. Event Director Douglas Lugo said outsourcing decisions do not happen in isolation but sit at the intersection of innovation, manufacturing readiness and capital. Early bird pricing ran to 30 January 2026.